Wyeth

American Home Products Corporation

Other

Zoetis Services LLC

Boehringer Ingelheim Vetmedica Gmbh

China Agricultural University

Zoetis W LLC

Hsien-jue Chu

Hsien-Jue Chu

Zhichang Xu

Wumin Li

Lloyd G Chavez

Terri Wasmoen

Bin Wang

Terry Kaleung Ng

Huali Jin

Youmin Kang

William M Acree

Lucille W Chang

Michael A Gill

Yu-Wei Chiang

Stephen Qitu Wu

Nicole Rae Gibson

Kaleung Ng

Thomas Jay Hess

Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and aallergenic protein are disclosed.

Allergy inhibitor compositions and kits and methods of using the same

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

[object Object]

Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or amelioratinginfection. Administration to an animal of one or two doses of an adjuvanted live avirulentcomposition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain ofthereby reducing the severity of and/or preventing disease caused by one or more virulent strain of. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulentand compositions, comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) in further combination with an adjuvanted live avirulent

Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and aallergenic protein are disclosed.

The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.

Raccoon poxvirus expressing rabies glycoproteins

Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein. The kits comprise a first container which comprises a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein and a second container which comprises an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein. Compositions and kits for inhibiting an allergic response against an flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed. Methods if using such compositions and kits are also disclosed.

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Mycoplasma hyopneumoniae bacterin vaccine

The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.

Methods for prevention or amelioration of West Nile encephalitis using a West Nile DNA vaccine

West nile DNA vaccine

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Methods for preventing or ameliorating West Nile encephalitis

The invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedbacterin and an adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL&#xae;, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC&#xae;. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improvedbacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedbacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity frominfection after a single administration, and elicit an immune response specific tobacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Growing community of inventors

Fort Dodge, IA, United States of America

Hsien-Jue Chu